Cause‐Specific Mortality and Prognostic Impact of Comorbidity in Japanese Patients With Chronic Lymphocytic Leukemia

Documenti analoghi

• Healthcare Resource Utilization and Costs in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Treated With Covalent Bruton's Tyrosine Kinase Inhibitors: Real‐World Impact of Cardiovascular Adverse Events
  di: Mavis Obeng‐Kusi, et al.
  Pubblicazione: (2025)
• Effect of Statins in the Watch and Wait Phase of Chronic Lymphocytic Leukemia
  di: David E. Spaner
  Pubblicazione: (2025)
• Efficacy and Effectiveness Outcomes of Treatments for Double‐Exposed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients: A Systematic Literature Review
  di: Mohammed Zuber, et al.
  Pubblicazione: (2024)
• Incidence, Prevalence, Survival and Mortality of Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma and Waldenström Macroglobulinaemia in Australia
  di: Dieu Nguyen, et al.
  Pubblicazione: (2026)
• Adverse Effects of Low Serum HDL ‐C Levels on Prognosis and Tumor Immune Microenvironment in Patients With Newly Diagnosed Chronic Lymphocytic Leukemia
  di: Weiran Lv, et al.
  Pubblicazione: (2026)